Reduced-Intensity Conditioning Is Effective for Hematopoietic Stem Cell Transplantation in Young Pediatric Patients with Diamond-Blackfan Anemia

Researchers retrospectively compared the outcomes of Diamond-Blackfan anemia patients who underwent hematopoietic stem cell transplantation using either myeloablative conditioning or reduced-intensity conditioning regimens.
[Bone Marrow Transplantation]
Koyamaishi, S., Kamio, T., Kobayashi, A., Sato, T., Kudo, K., Sasaki, S., Kanezaki, R., Hasegawa, D., Muramatsu, H., Takahashi, Y., Sasahara, Y., Hiramatsu, H., Kakuda, H., Tanaka, M., Ishimura, M., Nishi, M., Ishiguro, A., Yabe, H., Sarashina, T., … Ito, E. (2020). Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond–Blackfan anemia. Bone Marrow Transplantation, 1–8. https://doi.org/10.1038/s41409-020-01056-1 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Preclinical Evaluation of a Regimen Combining Chidamide and ABT-199 in Acute Myeloid Leukemia

Scientists reported that a newly emerged histone deacetylase inhibitor, chidamide, at low-cytotoxicity dose enhanced the anti-AML activity of ABT-199, while sparing normal hematopoietic progenitor cells.
[Cell Death & Disease]
Chen, K., Yang, Q., Zha, J., Deng, M., Zhou, Y., Fu, G., Bi, S., Feng, L., Xu-Monette, Z. Y., Chen, X. L., Fu, G., Dai, Y., Young, K. H., & Xu, B. (2020). Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death & Disease, 11(9), 1–13. https://doi.org/10.1038/s41419-020-02972-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Multi-Layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development

To identify secreted signals underlying human hematopoietic stem cell development, scientists combined spatial transcriptomics analysis of dorsoventral polarized signaling in the aorta with gene expression profiling of sorted cell populations and single cells.
[Cell Stem Cell]
Crosse, E. I., Gordon-Keylock, S., Rybtsov, S., Binagui-Casas, A., Felchle, H., Nnadi, N. C., Kirschner, K., Chandra, T., Tamagno, S., Webb, D. J., Rossi, F., Anderson, R. A., & Medvinsky, A. (2020). Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. Cell Stem Cell, 0(0). https://doi.org/10.1016/j.stem.2020.08.004 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Unraveling Hematopoiesis through the Lens of Genomics

Researchers describe how recently uncovered complexities are reshaping the concept of tissue development and homeostasis while opening up a more comprehensive future understanding of hematopoiesis.
[Cell]
Liggett, L. A., & Sankaran, V. G. (2020). Unraveling Hematopoiesis through the Lens of Genomics. Cell, 182(6), 1384–1400. https://doi.org/10.1016/j.cell.2020.08.030 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Vast Self-Renewal Potential of Human AGM Region HSCs Dramatically Declines in the Umbilical Cord Blood

Researchers showed that a single human aorta-gonad-mesonephros region hematopoietic stem cell (HSC) could generate 600–1,600 functional daughter HSCs.
[Stem Cell Reports]
Vast Self-Renewal Potential of Human AGM Region HSCs Dramatically Declines in the Umbilical Cord Blood: Stem Cell Reports. (n.d.). Retrieved September 18, 2020, from https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(20)30339-8 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Scientists employed disease modeling in vitro by the use of customizable induced pluripotent stem cells to generate a transient abnormal myelopoiesis model.
[Molecular Therapy-Methods & Clinical Development]
Barwe, S. P., Sidhu, I., Kolb, E. A., & Gopalakrishnapillai, A. (2020). Modeling transient abnormal myelopoiesis using induced pluripotent stem cells and CRISPR/Cas9 technology. Molecular Therapy - Methods & Clinical Development, 0(0). https://doi.org/10.1016/j.omtm.2020.09.007 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

The Lysophospholipase D Enzyme Gdpd3 Is Required to Maintain Chronic Myelogenous Leukemia Stem Cells

Investigators showed that disruption of the Gdpd3 gene encoding a lysophospholipase D enzyme significantly decreased self-renewal capacity in murine chronic myelogenous leukemia stem cells in vivo.
[Nature Communications]
Naka, K., Ochiai, R., Matsubara, E., Kondo, C., Yang, K.-M., Hoshii, T., Araki, M., Araki, K., Sotomaru, Y., Sasaki, K., Mitani, K., Kim, D.-W., Ooshima, A., & Kim, S.-J. (2020). The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells. Nature Communications, 11(1), 4681. https://doi.org/10.1038/s41467-020-18491-9 Cite
Full ArticlePress Release
Bookmark

No account yet? Register

0
Share

Autologous Hematopoietic Stem Cell Transplant in Systemic Sclerosis Is Associated with Marked Improvement in Health‐Related Quality of Life

Scientists quantified the magnitude, domains and duration of change in health‐related quality of life in patients with systemic sclerosis (SSc) treated with autologous hematopoietic stem cell transplantation (AHSCT) compared to similar SSc patients who did not undergo AHSCT.
[Arthritis & Rheumatology]
Maltez, N., Puyade, M., Wang, M., Lansiaux, P., Marjanovic, Z., Charles, C., Steele, R., Baron, M., Colmegna, I., Hudson, M., & Farge, D. (n.d.). Autologous hematopoietic stem cell transplant in systemic sclerosis is associated with marked improvement in health-related quality of life. Arthritis & Rheumatology, n/a(n/a). https://doi.org/10.1002/art.41519 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

Gilead Sciences, Inc. announced that the FDA has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome.
[Gilead Sciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML

Cullinan Oncology, LLC, the German Cancer Research Center and the Eberhard Karls University of Tübingen, Faculty of Medicine announced the formation of Cullinan Florentine, a company focused on developing a novel FLT3 x CD3 bispecific antibody for the treatment of patients with acute myeloid leukemia (AML).
[Cullinan Oncology, LLC]
Press Release
Bookmark

No account yet? Register

0
Share

BCL6 Maintains Survival and Self-Renewal of Primary Human Acute Myeloid Leukemia Cells

Scientists explored the role of BCL6 in acute myeloid leukemia (AML). BCL6 was expressed at variable and often high levels in AML cell lines and primary AML samples.
[Blood]
Kawabata, K. C., Zong, H., Meydan, C., Wyman, S., Wouters, B. J., Sugita, M., Goswami, S., Albert, M., Yip, W., Roboz, G. J., Chen, Z., Delwel, R., Carroll, M. P., Mason, C., Melnick, A., & Guzman, M. L. (n.d.). BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. https://doi.org/10.1182/blood.2019001745 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share